The present invention relates to a carbon sorbent the can selectively remove platinum-group metals and other heavy metals such as tin without co-removing organic synthesis products including pharmaceutical intermediates and finished Active Pharmaceutical Ingredients (APIs). The carbon sorbents of the present invention are made from low-cost, high purity starting materials and the resulting carbon sorbents are also very pure. The carbon sorbents possess a combination of certain nitrogen and phosphorous groups combined with mesoporosity (2 to 50 nm diameter pores) that proves the high metal adsorption.

The present invention relates to a carbon sorbent the can selectively remove platinum-group metals and other heavy metals such as tin without co-removing organic synthesis products including pharmaceutical intermediates and finished Active Pharmaceutical Ingredients (APIs). The carbon sorbents of the present invention are made from low-cost, high purity starting materials and the resulting carbon sorbents are also very pure. The carbon sorbents possess a combination of certain nitrogen and phosphorous groups combined with mesoporosity (2 to 50 nm diameter pores) that proves the high metal adsorption.

The present invention relates to compositions of pibrentasvir, drug products thereof, and processes and intermediates for the preparation thereof. This invention relates to the drug product, active drug substance, intermediates, and processes of pibrentasvir, a NS5A inhibitor that is useful in the treatment of hepatitis C.

The present invention relates to compositions of pibrentasvir, drug products thereof, and processes and intermediates for the preparation thereof. This invention relates to the drug product, active drug substance, intermediates, and processes of pibrentasvir, a NS5A inhibitor that is useful in the treatment of hepatitis C.

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

An elegant process for the synthesis of 2-nitratoethyl acrylate is a single reactive step. A 2-hydroxyethyl acrylate having only one hydroxyl group is nitrated in a 1:1 volumetric mixture of nitric acid and sulfuric acid therein forming 2-nitratoethyl acrylate. The 2-nitratoethyl acrylate is minimally soluble in a quenched cold acid water mixture, which enables relatively easy isolation of about 96% purity 2-nitratoethyl acrylate at a yield of about 85%.

An elegant process for the synthesis of 2-nitratoethyl acrylate is a single reactive step. A 2-hydroxyethyl acrylate having only one hydroxyl group is nitrated in a 1:1 volumetric mixture of nitric acid and sulfuric acid therein forming 2-nitratoethyl acrylate. The 2-nitratoethyl acrylate is minimally soluble in a quenched cold acid water mixture, which enables relatively easy isolation of about 96% purity 2-nitratoethyl acrylate at a yield of about 85%.

The present invention relates to zeolite adsorbents based on agglomerated zeolite X crystals comprising barium, potassium and sodium. These adsorbents find applications in the separation of aromatic C8 isomer fractions and especially xylene.

The present invention relates to zeolite adsorbents based on agglomerated zeolite X crystals comprising barium, potassium and sodium. These adsorbents find applications in the separation of aromatic C8 isomer fractions and especially xylene.